LXXGQ / LexaGene Holdings Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

REVOKED

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SECURITIES EXCHANGE ACT OF 1934 Release No. 102795 / April 9, 2025 Admin. Proc. File No. 3-22071 In the Matter of LEXAGENE HOLDINGS INC. OPINION OF THE COMMISSION SECTION 12(j) PROCEEDING Grounds for Remedial Action Failure to Comply with Periodic Filing Requirements Company failed to file periodic reports in violation of Section 13(a) of the Sec

LexaGene Files for Chapter 7 Bankruptcy

Exhibit 99.1 LexaGene Files for Chapter 7 Bankruptcy BEVERLY, Mass. USA – Feb 24, 2023 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics Diagnostics, Inc., filed a voluntary petition for relief under Chapter 7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 LEXAGENE HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter)

S-8 1 forms8.htm FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia (State or other jurisdiction of incorporation or organization) None (I.R.S. Employer Identification No.) 500 Cummings Center, Suite 4550, Beverly, Massachusetts 01915 (Address of principal executive

Calculation of Filing Fee Tables Form S-8 LEXAGENE HOLDINGS INC. Table 1: Newly Registered Securities

Calculation of Filing Fee Tables Form S-8 LEXAGENE HOLDINGS INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value 457(h) 3,471,950(2) $0.39(5) $1,354,060 $110.20 per $1,000,000 $149.22 Equi

LexaGene Provides Update on BioPharma Sector

Exhibit 99.1 LexaGene Provides Update on BioPharma Sector BEVERLY, Mass. USA – Feb 8, 2023 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLabTM System for automated, genetic testing, is pleased to provide the following update on the Company’s efforts to have the MiQLab System adopted f

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organiz

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation) (Commissi

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organiz

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers

Exhibit 99.1 LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers BEVERLY, Mass. USA – Jan 18, 2023 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLabTM System for automated, genetic testing, is pleased to announce exciting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 formdef14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Check the appropriate box: Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 formdefa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Check the appropriate box: Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio

BioPharma Engages LexaGene in Second Feasibility Study Cancels Plans to Reprice Meridian’s Warrants

Exhibit 99.1 BioPharma Engages LexaGene in Second Feasibility Study Cancels Plans to Reprice Meridian?s Warrants BEVERLY, Mass. USA ? Dec 16, 2022 ? LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (?LexaGene? or the ?Company?), an innovative, molecular diagnostics company that has commercialized the MiQLab? System for automated, genetic testing, is pleased to announce the large biopharma compa

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organi

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organiz

LexaGene Holdings Proposes to Amend Warrants Terms

EX-99.1 2 tm2232121d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 LexaGene Holdings Proposes to Amend Warrants Terms BEVERLY, Mass. USA – Dec 7, 2022 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, announces that it intends to amend the exercise price

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organi

LexaGene Successfully Completes Statement of Work for BioPharma Company

Exhibit 99.1 LexaGene Successfully Completes Statement of Work for BioPharma Company BEVERLY, Mass. USA – Nov 22, 2022 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce the completion of a validation study with a major bio

Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organiz

LexaGene Closes Secured Convertible Note Transaction

Exhibit 99.1 LexaGene Closes Secured Convertible Note Transaction BEVERLY, Mass. USA – November 1, 2022 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it has issued a 12% secured convertible note (the “Note”) to Meridian LGH Holdings 2

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organiz

LexaGene Holdings Proposes to Amend Warrants Terms

EX-99.1 2 tm2229104d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 LexaGene Holdings Proposes to Amend Warrants Terms BEVERLY, Mass. USA – October 27, 2022 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it intends to amend the exercise price of

Secured Convertible Note Agreement

EX-10.1 2 tm2228906d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version SECURED CONVERTIBLE NOTE AGREEMENT This Agreement made effective October 24, 2022 (the “Effective Date”) BETWEEN: LEXAGENE HOLDINGS INC., a corporation incorporated under the Laws of British Columbia and having its principal place of business at 500 Cummings Center, Suite 4550, Beverly, Massachusetts 01915 (the “Borrower”)

Financial Statements and Exhibits, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia 000-56456 None (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: August 31, 2022 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-56456 LEXAGE

LETTER

United States securities and exchange commission logo August 26, 2022 Jack Regan Chief Executive Officer LexaGene Holdings Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10/A (Amendment No. 1) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 LEXAGENE HOLDINGS INC. (Exact name

10-12G/A 1 tm2210382d21012ga.htm 10-12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10/A (Amendment No. 1) GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia (State or other jurisdiction of incorporation o

Via EDGAR Correspondence

Reply to the Attention of Herbert I. Ono Direct Line (604) 691-7493 Direct Fax (604) 893-2398 Email Address [email protected] Our File No. 288224 Date August 9, 2022 Via EDGAR Correspondence United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 United States of America Attention: Division of Corporation Finance Office of Life Sciences Dear Sirs/Mesdames:

LETTER

United States securities and exchange commission logo July 25, 2022 Jack Regan Chief Executive Officer LexaGene Holdings Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 LEXAGENE HOLDINGS INC. (Exact name of registrant as sp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 LEXAGENE HOLDINGS INC. (Exact name of registrant as specified in its charter) British Columbia (State or other jurisdiction of incorporation or organization) 500 Cummings Center Suite 4550 Beverly, Massac

Amendment dated March 23, 2022 to Employment Agreement between LexaGene Holdings Inc. and Steven Armstrong1,2

Exhibit 10.3 [Certain portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.] EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), dated effective as of October 4, 2021 (the

Amendment to Lease #2 dated December 20, 2017 between LexaGene, Inc. and Cummings Properties, LLC1

Exhibit 10.12 AMENDMENT TO LEASE #2 In connection with a lease in effect between Cummings Properties, LLC, LESSOR, and LexaGrene, Inc. LESSEE, at 500 Cummings Center, Suite 4550, Beverly , Massachusetts (?premises? or ?leased premises?), fully executed on December 20, 2017, and in consideration of the mutual benefits to be derived herefrom, the parties hereby agree to amend said lease, including i

Amendment One To Limited Exclusive Patent License Agreement dated February 1, 2017 between Lawrence Livermore National Security, LLC and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene Holdings, Inc.1

Exhibit 10.6 AMENDMENT ONE To LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Food Safety, Water Quality Monitoring, and Human/Veterinary Clinical Diagnostics Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc. LLNL Case No. TL02679.1 Lawrence Livermore National Laboratory Industrial Partnership

Limited Exclusive Patent License Agreement dated May 20, 20151

Exhibit 10.5 [Certain portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.] LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Environmental Surveillance, Food Testing

Subsidiaries of LexaGene Holdings Inc.1

Exhibit 21.1 List of Subsidiaries Entity Jurisdiction Bionomics Diagnostics Inc. British Columbia, Canada LexaGene, Inc.* Massachusetts * LexaGene, Inc. is a second-tier subsidiary of the Registrant, held through Bionomics Diagnostics Inc.

Omnibus Incentive Plan of the Company dated effective July 25, 2017, as amended1

Exhibit 10.4 LEXAGENE HOLDINGS INC. OMNIBUS INCENTIVE PLAN July 25, 2017, as amended July 12, 2018, July 16, 2019, October 5, 2020 and November 10, 2021 TABLE OF CONTENTS Article 1 INTERPRETATION 1 Section 1.1 Definitions 1 Section 1.2 Other Words and Phrases 6 Section 1.3 Gender 6 Section 1.4 Administration 6 Section 1.5 Delegation to Committee 7 Section 1.6 Incorporation of Terms of Plan 7 Secti

Amendment Six To Limited Exclusive Patent License Agreement dated January 24, 2022 between Lawrence Livermore National Security, LLC and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene Holdings, Inc.1

Exhibit 10.11 AMENDMENT SIX To LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Food Safety, Water Quality Monitoring, and Human/Veterinary Clinical Diagnostics Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc. LLNL Case No. TL02679 Lawrence Livermore National Laboratory Innovation and Partners

Amendment dated April 20, 2016 to Share Exchange Agreement among Wolfeye Resource Corp., Bionomics Diagnostics Inc. and all holders of shares of Bionomics Diagnostics Inc.1

Exhibit 2.3 SECOND AMENDMENT TO sHARE EXCHANGE AGREEMENT THIS AGREEMENT made effective as of the 20th day of April, 2016 AMONG: WOLFEYE RESOURCE CORP., a corporation existing under the laws of the Province of British Columbia, having an office at 459 ? 409 Granville Street, Vancouver, British Columbia, V6C 1T2 (?Wolfeye?) AND: BIONOMICS DIAGNOSTICS INC., a corporation existing under the laws of th

Amendment Two To Limited Exclusive Patent License Agreement dated August 4, 2017 between Lawrence Livermore National Security, LLC and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene Holdings, Inc.1

Exhibit 10.7 AMENDMENT TWO To LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Food Safety, Water Quality Monitoring, and Human/Veterinary Clinical Diagnostics Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc. LLNL Case No. TL02679.2 Lawrence Livermore National Laboratory Innovation and Partner

BUSINESS CORPORATIONS ACT LEXAGENE HOLDINGS INC. TABLE OF CONTENTS

EX-3.1 5 tm2210382d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 Number: BC0789477 BUSINESS CORPORATIONS ACT ARTICLES of LEXAGENE HOLDINGS INC. TABLE OF CONTENTS PART 1 INTERPRETATION 1 PART 2 SHARES AND SHARE CERTIFICATES 2 PART 3 ISSUE OF SHARES 4 PART 4 SHARE REGISTERS 5 PART 5 SHARE TRANSFERS 5 PART 6 TRANSMISSION OF SHARES 6 PART 7 PURCHASE, REDEEM OR OTHERWISE ACQUIRE SHARES 7 PART 8 BORROWING POWERS 8

Share Exchange Agreement among Wolfeye Resource Corp., Bionomics Diagnostics Inc. and all holders of shares of Bionomics Diagnostics Inc., dated November 17, 2015 1,2

Exhibit 2.1 [Certain portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.] SHARE EXCHANGE AGREEMENT THIS AGREEMENT is made effective as of November 17, 2015 (the “Effective Date”). AMO

Amendment Four To Limited Exclusive Patent License Agreement dated September 18, 2019 between Lawrence Livermore National Security, LLC and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene Holdings, Inc.1

Exhibit 10.9 AMENDMENT FOUR To LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Food Safety, Water Quality Monitoring, and Human/Veterinary Clinical Diagnostics Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc. LLNL Case No. TL02679.4 Lawrence Livermore National Laboratory Innovation and Partne

Amendment Five To Limited Exclusive Patent License Agreement dated April 12, 2021 between Lawrence Livermore National Security, LLC and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene Holdings, Inc.1

Exhibit 10.10 AMENDMENT FIVE To LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Food Safety, Water Quality Monitoring, and Human/Veterinary Clinical Diagnostics Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc. LLNL Case No. TL02679.5 Lawrence Livermore National Laboratory Innovation and Partn

Amendment dated April 1, 2021 to Employment Agreement between LexaGene Holdings Inc. and Dr. Jack Regan1,2

Exhibit 10.1 [Certain portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.] EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), dated effective as of December 12, 2018 (t

Warrant Indenture dated as of October 29, 2019 between LexaGene Holdings Inc. and Computershare Trust Company of Canada, as warrant agent1

? Exhibit 4.1 ? LEXAGENE HOLDINGS INC. ? as the Corporation ? and ? COMPUTERSHARE TRUST COMPANY OF CANADA ? as the Warrant Agent ? ? WARRANT INDENTURE Providing for the Issue of Warrants ? Dated as of October 29, 2019 ? ? ? ? TABLE OF CONTENTS ? ? ? Page No. Article?1 INTERPRETATION Section?1.1??? Definitions 2 Section?1.2??? Gender and Number 6 Section?1.3??? Headings, Etc. 7 Section?1.4??? Day n

Letter of Manning Elliot LLP relating to change in certifying accountant dated June 22, 20221

Exhibit 16.1 June 22, 2022 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We, Manning Elliott LLP, were previously the auditor for LexaGene Holdings Inc. (the "Company") and, under the date of June 26, 2020, we reported on the consolidated financial statements of the Company as of and for the year ended February 29, 2020. Manning Elliott LLP resigned as the Company

Amendment dated April 1, 2021 to Employment Agreement between LexaGene Holdings Inc. and Jeffrey Mitchell1.2

Exhibit 10.2 [Certain portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.] EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), dated effective as of December 12, 2018 (t

Notice of Articles1

Exhibit 3.2 [Certain portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.] Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Vic

Investor Rights Agreement dated February 7, 2022 between LexaGene Holdings Inc. and Meridian LGH Holdings LLC1

Exhibit 4.3 INVESTOR RIGHTS AGREEMENT THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of February 7, 2022, by and among LexaGene Holdings Inc., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”), and Meridian LGH Holdings, LLC, a limited liability company formed under the Texas Business Organizations Code (the “Investor”). Recitals WHERE

Warrant Indenture dated as of September 9, 2020 between LexaGene Holdings Inc. and Computershare Trust Company of Canada, as warrant agent1

Exhibit 4.2 LEXAGENE HOLDINGS INC. as the Corporation and COMPUTERSHARE TRUST COMPANY OF CANADA as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of September 9, 2020 TABLE OF CONTENTS Page No. Article 1 INTERPRETATION Section 1.1 Definitions 2 Section 1.2 Gender and Number 4 Section 1.3 Headings, Etc. 5 Section 1.4 Day not a Business Day 5 Section 1.5 Time of the

Amendment Three To Limited Exclusive Patent License Agreement dated September 14, 2017 between Lawrence Livermore National Security, LLC and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene Holdings, Inc.1

Exhibit 10.8 AMENDMENT THREE To LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT For DIAGNOSTIC KIOSK For Food Safety, Water Quality Monitoring, and Human/Veterinary Clinical Diagnostics Between LAWRENCE LIVERMORE NATIONAL SECURITY, LLC and BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc. LLNL Case No. TL02679.3 Lawrence Livermore National Laboratory Innovation and Partn

Amendment dated January 28, 2016 to Share Exchange Agreement among Wolfeye Resource Corp., Bionomics Diagnostics Inc. and all holders of shares of Bionomics Diagnostics Inc.1

Exhibit 2.2 AMENDMENT TO sHARE EXCHANGE AGREEMENT THIS AGREEMENT made effective as of the 28th day of January, 2016 AMONG: WOLFEYE RESOURCE CORP., a corporation existing under the laws of the Province of British Columbia, having an office at 459 ? 409 Granville Street, Vancouver, British Columbia, V6C 1T2 (?Wolfeye?) AND: BIONOMICS DIAGNOSTICS INC., a corporation existing under the laws of the Pro